Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC

References

• American Cancer SocietyCancer Facts and Figures, 2010Atlanta, GAAmerican Cancer Society2010
   Google Scholar
• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin20106027730020610543
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology™ Non-Small Cell Lung Cancer. V.2.2010. Available from: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed April 8, 2010.
   Google Scholar
• BreathnachOSFreidlinBConleyBTwenty-two years of Phase III trials for patients with advanced non-small-cell lung cancer: sobering resultsJ Clin Oncol20011961734174211251004
   PubMed Web of Science ®Google Scholar
• CarneyDNLung cancer – time to move on from chemotherapyN Engl J Med2002346212612811784881
   PubMed Web of Science ®Google Scholar
• ParkJOKimSWAhnJSPhase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancerJ Clin Oncol200725335233523918024869
   PubMed Web of Science ®Google Scholar
• SmithIEO’BrienMETalbotDCDuration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatinJ Clin Oncol20011951336134311230476
   PubMed Web of Science ®Google Scholar
• von PlessenCBergmanBAndresenOPalliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancerBr J Cancer200695896697317047644
   PubMed Web of Science ®Google Scholar
• Tarceva® (erlotinib tablets) [package insert]South San Franscisco, CA Genentech, Inc.
   Google Scholar
• Iressa® (gefitinib tablets) [package insert]Wilmington, DEAstraZeneca Pharmaceuticals LP
   Google Scholar
• Avastin® (bevacizumab) [package insert]South San Francisco, CAGenentech, Inc.2009
   Google Scholar
• SharmaSVBellDWSettlemanJHaberDAEpidermal growth factor receptor mutations in lung cancerNat Rev Cancer20077316918117318210
   PubMed Web of Science ®Google Scholar
• CohenMHWilliamsGASridharaRChenGPazdurRFDA drug approval summary: gefitinib (ZD1839) (Iressa) tabletsOncologist20038430330612897327
   PubMed Web of Science ®Google Scholar
• FukuokaMYanoSGiacconeGMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]J Clin Oncol200321122237224612748244
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1J Clin Oncol200422577778414990632
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2J Clin Oncol200422578579414990633
   PubMed Web of Science ®Google Scholar
• GautschiOMackPCDaviesAMJablonsDMRosellRGandaraDRPharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directionsClin Lung Cancer20089Suppl 3S129S13819419927
   PubMed Web of Science ®Google Scholar
• KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trialLancet200837296521809181819027483
   PubMed Web of Science ®Google Scholar
• MaruyamaRNishiwakiYTamuraTPhase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancerJ Clin Oncol200826264244425218779611
   PubMed Web of Science ®Google Scholar
• AstraZeneca. IRESSA (Gefitinib) receives marketing authorisation for the treatment of non-small cell lung cancer in Europe http://www.astrazeneca.com/Media/Press-releases/Article/20090701-IRESSA-Gefitinib-Receives-Marketing-Authorisation-f. Accessed April 8, 2010.
   Google Scholar
• Erlotinib (Tarceva) for advanced non-small cell lung cancerMed Lett Drugs Ther20054712052526
   Web of Science ®Google Scholar
• ShepherdFARodriguesPJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• Genentech IncFDA approves Tarceva as a maintenance therapy for advanced non-small cell lung cancer http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=12727. Accessed April 21, 2010.
   Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol201011652152920493771
   PubMed Web of Science ®Google Scholar
• JackmanDMYeapBYSequistLVExon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibClin Cancer Res200612133908391416818686
   PubMed Web of Science ®Google Scholar
• MitsudomiTKosakaTEndohHMutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrenceJ Clin Oncol200523112513252015738541
   PubMed Web of Science ®Google Scholar
• RielyGJPaoWPhamDClinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinibClin Cancer Res2006123 Pt 183984416467097
   PubMed Web of Science ®Google Scholar
• EngelmanJAJannePAMechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerClin Cancer Res200814102895289918483355
   PubMed Web of Science ®Google Scholar
• KerbelRSAntiangiogenic therapy: a universal chemosensitization strategy for cancer?Science200631257771171117516728631
   PubMed Web of Science ®Google Scholar
• CarmelietPAngiogenesis in life, disease and medicineNature2005438707093293616355210
   PubMed Web of Science ®Google Scholar
• KreuterMKropffMFischaleckAPrognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatmentEur Respir J20093361383138819213790
   PubMed Web of Science ®Google Scholar
• MeertAPPaesmansMMartinBThe role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysisBr J Cancer200287769470112232748
   PubMed Web of Science ®Google Scholar
• WeidnerNIntratumor microvessel density as a prognostic factor in cancerAm J Pathol199514719197541613
   PubMed Web of Science ®Google Scholar
• Avastin® (Bevacizumab) for intravenous use [package insert]South San Francisco, CAGenentech, Inc.2008
   Google Scholar
• JohnsonDHFehrenbacherLNovotnyWFRandomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol200422112184219115169807
   PubMed Web of Science ®Google Scholar
• HapaniSSherAChuDWuSIncreased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysisOncology2010791–2273821051914
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiLJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPOverall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Ann Oncol20102191804180920150572
   PubMed Web of Science ®Google Scholar
• KabbinavarFFMillerVAJohnsonBEO’ConnorPGSohCTlasIOverall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)J Clin Oncol.20102815s Abstract 7526.
   Google Scholar
• PolikoffJHainsworthJDFehrenbacherLSafety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLASJ Clin Oncol.20082615s Abstract 8079.
   Google Scholar
• HainsworthJDFangLHuangJEBRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancerJ Thorac Oncol20116110911421107290
   PubMed Web of Science ®Google Scholar
• ArdizzoniABoniLTiseoMCisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysisJ Natl Cancer Inst2007991184785717551145
   PubMed Web of Science ®Google Scholar
• PatelJDHensingTARademakerAPhase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancerJ Clin Oncol200927203284328919433684
   PubMed Web of Science ®Google Scholar
• PatelJDBonomiPSocinskiMATreatment rationale and study design for the pointbreak study: a randomized, open-label Phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerClin Lung Cancer200910425225619632943
   PubMed Web of Science ®Google Scholar
• AdjeiAAMandrekarSJDyGKPhase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426J Clin Oncol201028461461919841321
   PubMed Web of Science ®Google Scholar
• HicklinDJEllisLMRole of the vascular endothelial growth factor pathway in tumor growth and angiogenesisJ Clin Oncol20052351011102715585754
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• NeufeldGKesslerOThe semaphorins: versatile regulators of tumour progression and tumour angiogenesisNat Rev Cancer20088863264518580951
   PubMed Web of Science ®Google Scholar
• JarvisAAllerstonCKJiaHSmall molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interactionJ Med Chem20105352215222620151671
   PubMed Web of Science ®Google Scholar
• BagriATessier-LavigneMWattsRJNeuropilins in tumor biologyClin Cancer Res20091561860186419240167
   PubMed Web of Science ®Google Scholar
• FukumuraDXavierRSugiuraTTumor induction of VEGF promoter activity in stromal cellsCell19989467157259753319
   PubMed Web of Science ®Google Scholar
• GerberHPKowalskiJShermanDEberhardDAFerraraNComplete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factorCancer Res200060226253625811103779
   PubMed Web of Science ®Google Scholar
• YuanAYuC-JKuoS-HVascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancerJ Clin Oncol200119243244111208836
   PubMed Web of Science ®Google Scholar
• DelmottePMartinBPaesmansMVEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis [in French]Rev Mal Respir2002195 Pt 157758412473944
   PubMed Web of Science ®Google Scholar
• BeenkenAMohammadiMThe FGF family: biology, pathophysiology and therapyNat Rev Drug Discov20098323525319247306
   PubMed Web of Science ®Google Scholar
• PrestaMDell’EraPMitolaSMoroniERoncaRRusnatiMFibroblast growth factor/fibroblast growth factor receptor system in angiogenesisCytokine Growth Factor Rev200516215917815863032
   PubMed Web of Science ®Google Scholar
• MurakamiMZhengYHirashimaMVEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitmentArterioscler Thromb Vasc Biol200828465866418174461
   PubMed Web of Science ®Google Scholar
• KleinSGiancottiFGPrestaMAlbeldaSMBuckCARifkinDBBasic fibroblast growth factor modulates integrin expression in microvascular endothelial cellsMol Biol Cell19934109739828298194
   PubMed Web of Science ®Google Scholar
• UnderwoodPABeanPAGambleJRRate of endothelial expansion is controlled by cell:cell adhesionInt J Biochem Cell Biol2002341556911733185
   PubMed Web of Science ®Google Scholar
• RusnatiMPrestaMFibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategiesCurr Pharm Des200713202025204417627537
   PubMed Web of Science ®Google Scholar
• BeitzJGKimISCalabresiPFrackeltonARJrHuman microvascular endothelial cells express receptors for platelet-derived growth factorProc Natl Acad Sci U S A1991885202120251848018
   PubMed Web of Science ®Google Scholar
• WuEPalmerNTianZComprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cellsPLoS One2008311e379419030102
   PubMed Web of Science ®Google Scholar
• LindahlPJohanssonBRLeveenPBetsholtzCPericyte loss and microaneurysm formation in PDGF-B-deficient miceScience199727753232422459211853
   PubMed Web of Science ®Google Scholar
• AbramssonALindblomPBetsholtzCEndothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumorsJ Clin Invest200311281142115114561699
   PubMed Web of Science ®Google Scholar
• HellstromMKalenMLindahlPAbramssonABetsholtzCRole of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouseDevelopment1999126143047305510375497
   PubMed Web of Science ®Google Scholar
• OikawaTOnozawaCSakaguchiMMoritaIMurotaSThree isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivoBiol Pharm Bull19941712168616887537574
   PubMed Web of Science ®Google Scholar
• RisauWDrexlerHMironovVPlatelet-derived growth factor is angiogenic in vivoGrowth Factors1992742612661284870
   PubMed Web of Science ®Google Scholar
• LevitzkiAPDGF receptor kinase inhibitors for the treatment of PDGF driven diseasesCytokine Growth Factor Rev200415422923515207814
   PubMed Web of Science ®Google Scholar
• KimKJLiBWinerJInhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature199336264238418447683111
   PubMed Web of Science ®Google Scholar
• FerraraNDavis-SmythTThe biology of vascular endothelial growth factorEndocr Rev19971814259034784
   PubMed Web of Science ®Google Scholar
• CasanovasOHicklinDJBergersGHanahanDDrug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell20058429930916226705
   PubMed Web of Science ®Google Scholar
• BergersGSongSMeyer-MorseNBergslandEHanahanDBenefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJ Clin Invest200311191287129512727920
   PubMed Web of Science ®Google Scholar
• ErberRThurnherAKatsenADCombined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanismsFASEB J200418233834014657001
   PubMed Web of Science ®Google Scholar
• KanoMRMorishitaYIwataCVEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signalingJ Cell Sci2005118Pt 163759376816105884
   PubMed Web of Science ®Google Scholar
• NissenLJCaoRHedlundEMAngiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasisJ Clin Invest2007117102766277717909625
   PubMed Web of Science ®Google Scholar
• SpratlinJLCohenRBEadensMPhase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2J Clin Oncol201028578078720048182
   PubMed Web of Science ®Google Scholar
• CamidgeDRBallasMSDubeySA phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC)J Clin Oncol.20102815s Abstract 7588.
   Google Scholar
• HilbergFRothGJKrssakMBIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacyCancer Res200868124774478218559524
   PubMed Web of Science ®Google Scholar
• RothGJHeckelAColbatzkyFDesign, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)J Med Chem200952144466448019522465
   PubMed Web of Science ®Google Scholar
• MrossKStefanicMGmehlingDPhase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumorsClin Cancer Res201016131131920028771
   PubMed Web of Science ®Google Scholar
• OkamotoIKanedaHSatohTPhase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumorsMol Cancer Ther20109102825283320688946
   PubMed Web of Science ®Google Scholar
• EllisPMKaiserRZhaoYStopferPGyorffySHannaNPhase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patientsClin Cancer Res201016102881288920460487
   PubMed Web of Science ®Google Scholar
• ReckMKaiserREschbachCA Phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancerAnn Oncol. Epub 2011 Jan 6.
   Google Scholar
• Alimta® (pemetrexed disodium) [package insert]Indianapolis, INEli Lilly and Company122009
   Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRJrGatzemeierUFossellaFPhase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancerJ Clin Oncol200927264274428019652055
   PubMed Web of Science ®Google Scholar
• SchillerJHLeeJWHannaNHTraynorAMCarboneDPA randomized discontinuation Phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501J Clin Oncol.20082615S Abstract 8014.
   Google Scholar
• ScagliottiGNovelloSvon PawelJPhase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancerJ Clin Oncol201028111835184220212250
   PubMed Web of Science ®Google Scholar
• Bayer Healthcare Pharmaceuticals IncOnyx Pharmaceuticals IncPhase 3 trial of nexavar in first-line advanced non-small cell lung cancer does not meet primary endpoint of overall survival Press release. June 14, 2010. Available from: http://www.onyx-pharm.com/view.cfm/685/Phase-3-Trial-of-Nexavar-in-First-Line-Advanced-Non-Small-Cell-Lung-Cancer-Does-Not-Meet-Primary-Endpoint-of-Overall-Survival. Accessed July 27, 2010.
   Google Scholar
• SunLLiangCShirazianSDiscovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinaseJ Med Chem20034671116111912646019
   PubMed Web of Science ®Google Scholar
• SocinskiMANovelloSBrahmerJRMulticenter, Phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancerJ Clin Oncol200826465065618235126
   PubMed Web of Science ®Google Scholar
• NovelloSScagliottiGVRosellRPhase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerBr J Cancer200910191543154819826424
   PubMed Web of Science ®Google Scholar
• NikolinakosPHeymachJVThe tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignanciesJ Thorac Oncol200836 Suppl 2S131S13418520296
   PubMed Web of Science ®Google Scholar
• WedgeSRKendrewJHennequinLFAZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerCancer Res200565104389440015899831
   PubMed Web of Science ®Google Scholar
• GossGDArnoldAShepherdFARandomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 studyJ Clin Oncol2010281495519917841
   PubMed Web of Science ®Google Scholar
• GadgeelSMWozniakAEdelmanMJCediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC)J Clin Oncol.20092715S Abstract e19007.
   Google Scholar
• AlbertDHTapangPMagocTJPreclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorMol Cancer Ther200654995100616648571
   PubMed Web of Science ®Google Scholar
• ShankarDBLiJTapangPABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemiaBlood200710983400340817209055
   PubMed Web of Science ®Google Scholar
• TanESalgiaRBesseBABT-869 in non-small cell lung cancer (NSCLC): interim resultsJ Clin Oncol.20092715S Abstract 8074.
   Google Scholar
• PolverinoACoxonAStarnesCAMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenograftsCancer Res200666178715872116951187
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRKabbinavarFFMenonHRandomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC)J Clin Oncol20102815s7528
   Web of Science ®Google Scholar
• PriceTJLiptonLMcGreivyJMcCoySSunYNRosenthalMASafety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumoursBr J Cancer20089991387139418971935
   PubMed Web of Science ®Google Scholar
• Amgen. Independent Data Monitoring Committee recommends resuming enrollment of non-squamous NSCLC patients in the motesanib MONET1 trial. http://www.amgen.com/media/media_pr_detail.jsp?year=2009&releaseID=1255738. Accessed May 12, 2010.
   Google Scholar
• SloanBScheinfeldNSPazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapyCurr Opin Investig Drugs200891213241335
   PubMed Web of Science ®Google Scholar
• KumarRKnickVBRudolphSKPharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMol Cancer Ther2007672012202117620431
   PubMed Web of Science ®Google Scholar
• AltorkiNLaneMEBauerTPhase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancerJ Clin Oncol201028193131313720516450
   PubMed Web of Science ®Google Scholar
• RugoHSHerbstRSLiuGPhase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical resultsJ Clin Oncol200523245474548316027439
   PubMed Web of Science ®Google Scholar
• SchillerJHLarsonTOuSHEfficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a Phase II studyJ Clin Oncol200927233836384119597027
   PubMed Web of Science ®Google Scholar
• LockhartACRothenbergMLDupontJPhase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumorsJ Clin Oncol201028220721419949018
   PubMed Web of Science ®Google Scholar
• LeighlNBRaezLEBesseBA multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lungJ Thorac Oncol2010571054105920593550
   PubMed Web of Science ®Google Scholar
• IvySPWickJYKaufmanBMAn overview of small-molecule inhibitors of VEGFR signalingNat Rev Clin Oncol200961056957919736552
   PubMed Web of Science ®Google Scholar
• LababedeOMezianeMRiceTSeventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagramsChest2011139118318921208878
   PubMed Web of Science ®Google Scholar